It’s safe to say Ed Mathers has accrued some industry know-how after 35 years in the biopharmaceutical industry — 15 of which have been spent on the investor side of the business.
Mathers is now in his ninth year as a partner at New Enterprise Associates (NEA), a well-known firm that has been top-of-mind with the nomination of one of its venture partners, Scott Gottlieb, to the role of FDA commissioner. But that’s a different story.
